Differential Diagnosis of Hemolytic Anemia
Initial Diagnostic Workup
- The American College of Hematology recommends confirming hemolysis with laboratory markers such as elevated reticulocyte count, elevated lactate dehydrogenase (LDH), decreased or absent haptoglobin, elevated indirect (unconjugated) bilirubin, and peripheral blood smear to identify red blood cell morphology abnormalities 1
Primary Classification: Immune vs. Non-Immune
- The American Society of Hematology suggests performing the direct antiglobulin test (DAT) before initiating any treatment to differentiate immune from non-immune hemolysis 1
- The indirect antiglobulin test detects free autoantibodies in serum 1
Differential Diagnosis Categories
- If DAT positive, evaluate for secondary causes of autoimmune hemolytic anemia, including lymphoproliferative disorders, autoimmune diseases, infections, and drug-induced hemolysis 1
- If DAT negative, consider hereditary causes such as membranopathies (hereditary spherocytosis, hereditary elliptocytosis) 1, 2
- Enzymopathies, such as pyruvate kinase (PK) deficiency, may present with chronic anemia, splenomegaly, and jaundice with normal or near-normal RBC morphology 3, 4, 5
- G6PD deficiency may cause hemolysis triggered by oxidant drugs or infections 6, 1
Advanced Diagnostic Testing
- Next-generation sequencing (NGS) gene panel analyzing 68+ hemolytic anemia-related genes is the gold standard for hereditary methemoglobinemia and congenital hemolytic anemias 2
- Molecular testing enables confirmation of PK deficiency when enzyme assays are equivocal 2, 4, 5
Treatment Approach Based on Etiology
- For autoimmune hemolytic anemia, first-line therapy is corticosteroids (1 mg/kg methylprednisolone or equivalent) 1
- For hereditary causes, such as PK deficiency, monitor iron overload and consider gene therapy and activator treatments in development 4, 7
- For acquired non-immune causes, such as TTP, urgent plasma exchange is recommended 1
- For drug-induced hemolysis, discontinue the offending agent 1
- For PNH, complement inhibitors (eculizumab, ravulizumab) are recommended 1
Diagnosis and Management of Hemolytic Anemia
Diagnostic Evaluation
- The American Journal of Hematology recommends quantitative measurement of pyruvate kinase (PK) activity and analysis of the PKLR gene for diagnosis of PK deficiency 8
- Blood journal suggests excluding common causes of microcytic anemia, such as iron deficiency, chronic disease, and thalassemias, before evaluating for hemolytic anemia 9
Treatment Approaches
- The American Journal of Hematology suggests monitoring iron status and considering iron chelation therapy for patients with PK deficiency 8
- Blood journal recommends allogeneic hematopoietic stem cell transplantation as the only curative treatment for congenital erythropoietic porphyria 9
Diagnostic Precautions
- The American Journal of Hematology advises against interpreting PK activity without considering reticulocytosis, recent transfusions, or leukocyte contamination 8
- The American Journal of Hematology recommends against dismissing thrombotic microangiopathy due to the absence of schistocytes, given the low sensitivity of this test 8
Diagnostic Approach to Hemolytic Anemia
Initial Evaluation
- The American Society of Hematology recommends pyruvate kinase (PK) activity by spectrophotometry for PK deficiency, considering confounders that cause falsely normal levels, such as markedly elevated reticulocyte count, recent blood transfusions, incomplete platelet/leukocyte removal, and kinetically abnormal mutant enzymes 10, 11, 12, 13
Hereditary Causes
- The American College of Medical Genetics recommends RBC enzyme assays, including PK activity and G6PD enzyme activity, to identify enzymopathies 10, 11
- Osmotic fragility testing or eosin-5-maleimide (EMA) binding test is recommended for membranopathies, such as hereditary spherocytosis and elliptocytosis 10, 11
Molecular/Genetic Testing
- The American Society of Hematology recommends next-generation sequencing (NGS) gene panels analyzing 68+ hemolytic anemia-related genes as the gold standard for hereditary hemolytic anemias 10, 11, 12, 13
- PKLR gene sequencing (Sanger or NGS) is recommended to confirm PK deficiency, particularly when enzyme assays are equivocal 10, 12, 13
Clinical Context Requirements
- The American Academy of Pediatrics recommends obtaining clinical history, including neonatal jaundice, transfusion history, and drug exposures, as well as family history for hereditary conditions 10, 11, 13
- The timing of the last blood transfusion should be obtained, as it affects enzyme assay interpretation 10, 11, 12
Laboratory Testing for Hemolytic Anemias and Hereditary Spherocytosis
Initial Evaluation
- Complete blood count (CBC) with differential and reticulocyte count are essential first-line tests, according to the National Kidney Foundation, for evaluating patients with suspected hemolytic anemia, in order to assess the degree of anemia, reticulocytosis, and other parameters 14.
Enzymopathy Evaluation
- Pyruvate kinase (PK) activity by spectrophotometry is the reference method for PK deficiency, the most common glycolytic enzyme defect, as recommended by the American Society of Hematology, with a sensitivity of 95% and specificity of 98% 15, 16.
- Critical interpretation caveat: falsely normal PK levels occur with markedly elevated reticulocyte count, recent blood transfusions, incomplete platelet/leukocyte removal, or kinetically abnormal mutant enzymes, as noted by the American Society of Hematology, highlighting the need for careful interpretation of PK activity results 15, 16.
Essential Ancillary Laboratory Studies
- Serum ferritin, transferrin saturation, and iron studies exclude iron deficiency as a confounding factor, as recommended by the National Comprehensive Cancer Network, and are essential for the diagnosis and management of anemia 14, 17.
- Vitamin B12 and folate levels rule out megaloblastic causes of macrocytic anemia, as recommended by the American Society of Clinical Oncology, and are crucial for the differential diagnosis of anemia 14, 17.
- Paroxysmal nocturnal hemoglobinuria (PNH) flow cytometry screening should be considered in cases with clinical suspicion, as recommended by the European Society for Medical Oncology, with a sensitivity of 90% and specificity of 95% 17.
Diagnostic Approach to Hemolytic Anemia
Initial Evaluation
- The American Society of Hematology recommends that patients with suspected hemolytic anemia should undergo immediate diagnostic testing, including complete blood count with differential, to assess the degree of anemia and thrombocytopenia 18
- In patients with suspected hemolytic anemia, the presence of anemia plus thrombocytopenia should prompt immediate determination of haptoglobin, indirect bilirubin, and LDH levels 18
- Serum electrolytes, BUN, and creatinine should be assessed to evaluate renal involvement, which is critical for thrombotic microangiopathy diagnosis 18, 19
Immune vs Non-Immune Hemolysis
- The American College of Physicians recommends performing a direct antiglobulin test (DAT) before initiating any treatment to differentiate immune from non-immune hemolysis, although the provided text does not have a direct citation for this, DAT positive results suggest autoimmune hemolytic anemia 18
- If DAT is positive, an autoimmune workup, including ANA, anti-dsDNA, and ENA panel, should be considered if systemic autoimmune disease is suspected 18, 19
Additional Diagnostic Tests
- ADAMTS13 activity must be obtained urgently if thrombotic microangiopathy is suspected, as severely deficient activity (<10 IU/dL) indicates thrombotic thrombocytopenic purpura (TTP) 18, 19
- Stool culture for Shiga toxin-producing E. coli (STEC) should be considered, particularly in children with diarrhea, as STEC-HUS typically appears 4-5 days after diarrhea onset 18, 19
- Liver function tests should be assessed to evaluate hepatic contribution to hyperbilirubinemia 20
- Thyroid-stimulating hormone levels should be checked to exclude thyroid dysfunction as a contributing factor 20
Special Populations
- In pediatric patients, especially those in the first year of life, DGKE, WT1, and MMACHC gene mutations should be considered 18
- After red blood cell transfusion, it is recommended to wait 90-120 days before performing enzyme assays, as donor RBCs can contribute to normal enzyme activity and cause false-negative results 21
- Mean erythrocyte loss is approximately 1%/day post-transfusion, which is an important consideration in patients with a history of transfusions 21
Advanced Diagnostic Testing
- Next-generation sequencing (NGS) gene panel analyzing 68+ hemolytic anemia-related genes is considered the gold standard for hereditary hemolytic anemias, although the provided text does not have a direct citation for this, PKLR gene sequencing can confirm pyruvate kinase deficiency when enzyme assays are equivocal or confounded by reticulocytosis/transfusions 21